ISCT 2012 Annual Meeting Presentations
Share |

Academic Program

Corporate Guide


Event Photos
Photos from the ISCT 2012 Annual Meeting in Seattle, WA, USA
Photos from the Gala Dinner at the 2012 Annual Meeting
Note: The password to view photos is ISCT2012

Please note: Only those presentations where permission has been received for posting are available to meeting delegates. A large number of speakers are in the process of providing ISCT with revised slides and as a result, these presentations will be gradually uploaded to the website as they are received.

Reference to these materials will be useful but not comprehensive in developing appropriate standards of care. Their use does not confer any professional qualification or standard. Publication of these materials does not constitute an endorsement of ISCT. ISCT has not reviewed these materials to ensure consistency with acceptable practices. The views expressed in these materials represent the opinion of the authors. ISCT expressly disclaims any liability arising from any inaccuracy or misstatement. Each facility and/or individual referring to these materials should analyze the information, practices and procedures outlined therein to determine their acceptability for use in the context of their own obligations and within their own facility's standards and procedures.

Speakers for the following presentations have given authorization to post their materials.


Wednesday, June 6th

Technical Session 1- Imaging Cell Therapy

Chair: Rao Papineni (US)
Rao Papineni (US) – Multimodal Imaging in Cell Trafficking
Ali Arbab (US) – Imaging administered stem cells by in vivo imaging modalities

Technical Session 2 - NK Expansion for Clinical Trials

Chair: Didier Blaise (FR)
Didier Blaise (FR) – Role of NK cells in allogeneic SCT and perspectives
Jeffrey Miller (US) – How to educate NK cells to treat cancer

Strategies for Commercialization Track 1 - Best Practices in Cell Therapy Process Development

Chair: Jon Rowley (US)
Jon Rowley (US) – Designing High Impact Cell Therapy Process Development Programs
Andy Campbell (US) – Media and Process Development for Cell Therapy Applications: Implications for Scale-up and Manufacturing
Aby Mathew (US) – Designing Best Practices in Cell and Tissue Biopreservation for Clinical Process Development

Technical Applications Track 1- Daily Quality Assessments Performed by Cell Therapy Laboratory Staff

Chair: Victor Lemas (US)
Diane Kadidlo (US)
Olive Sturtevant (US)

Plenary Session 1 – Presidential Plenary on Mesenchymal Stem Cells

Chair: Ed Horwitz (USA)
Jacques Galipeau (US) – Mesenchymal Stromal Cells for personalized cell therapy. How mechanistic cell physiology studies can inform the design of clinical trials
Massimo Dominici (IT) – Revising Janus Bifrons myth for Cellular Therapies based on Mesenchymal Progenitors

Oral Abstract Presentations 1 – Cell and Gene Therapy/Immunotherapy and Dendritic Cells

Co-Chairs: Hans-Peter Kiem (US) and Catherine Bollard (US)

MGMTP140K Gene-Modified CD34+ Cells Allow for Increased Chemotherapy Administration and Extended Survival in Poor-Prognosis Glioblastoma Patients (Abstract # 1)
Speaker: Jennifer Adair(US)
A Single Infusion of Zinc Finger Nuclease (ZFN) CCR5 Modified Autologous CD4 T-Cells (SB-728-T) Correlates with Increases in CD4 Counts and Effects on Viral Load (VL) in Aviremic HIV-Infected Subjects (Abstract # 2)
Speaker: Bruce Levine (US)
CATS1 Study: Immunomonitoring and Clinical Results of Antigen-Specific T Regulatory (TREG) Cell Therapy for Crohn's Disease (CD) (Abstract # 3)
Speaker: Nathalie Clerget-Chossat (FR)
Combination Immunotherapy After ASCT for Advanced Myeloma with MAGE-A3/POLY-ICLC Immunization Followed by Transfer of Vaccine-Primed Activated Autologous T Cells (Abstract # 4)
Speaker: Nicole Aqui (US)
Effective Prophylaxis of CMV Disease in Recipients of Allogeneic Haemopoietic Stem Cell Transplants Using Adoptive T Cell Transfer-Long Term Follow-Up of 50 Patients (Abstract # 5)
Speaker: Emily Blyth (AU)

Oral Abstract Presentations 2 – Translational Process Development

Chairs: Jon Rowley (US)

Process Scale-Up and Transition from Autologous to Allogeneic Manufacturing of Cardiosphere-Derived Stem Cells (Abstract # 6)
Speaker: Michelle Kreke (US)
The Cryo-Imaging Solution to "Where Did My Cells Go" (Abstract # 7)
Speaker: David Wilson (US)
Navigating the First-In-Human Implantable Polymer-Derived Tumor Vaccines into a Clinical Trial (Abstract # 8)
Speaker: Heather Daley (US)
Development of an Angiogenic Potency Assay for Clinical Grade Stem Cell Production (Abstract # 9)
Speaker:Anthony Ting (US)
Developing Large Scale Cell Manufacturing Processes: The Impact on Cell Quality Attributes and Cost of Goods (Abstract # 10)
Speaker: Hemanthram Varadaraju (US)

Oral Abstract Presentations 3 – Cardiovascular Repair and Regeneration/Nervous System Repair

Co-Chairs: Warren Sherman (US) and Josef Priller (DE)

A Phase I/II Study Assessing the Safety and Efficacy of Intravenous Ex Vivo Cultured Adult Allogeneic Mesenchymal Stem Cells in Patients with ST Elevated Acute Myocardial Infarction (STEMI) (Abstract # 12)
Speaker: Pawan Gupta (IN)
IRES-Based Lentivirus Co-Expressing TGFB1 and FGF2 Improves Cell Survival and Angiogenesis in Bone Marrow Derived-Mesenchymal Stem Cells (Abstract # 13)
Speaker: Manuela Mura (IT)
A New Role for Meninges as a Niche for Stem/Precursor Cells with Neural Differentiation Potential During Development Up to Adulthood (Abstract # 14)
Speaker:Mauro Krampera (IT)
Safety and Efficacy of Intracoronary Infusion of Allogeneic Cardiosphere-Derived Stem Cells in a Pig Model of Myocardial Infarction (Abstract # 11)
Speaker: Rachel Smith (US)
Comparison of Human Schwann Cell Proliferation Rates in Culture from Organ Donor and Cadaveric Nerves (Abstract # 15)
Speaker: James Guest (US)

Strategies for Commercialization Track 2 - Biologics in Personalized Medicine- What are the Development Options beyond Phase 2?

Co-Chairs: Shirley Bartido (US) and David DiGiusto (US)
Renier Brentjens (USA) – Clinical translation of an adoptive therapeutic approach to Cancer: Obstacles from the perspectives of an academic investigator
Martin Schroeder (US) – Attracting Partners to Help Commercialize Cell Therapy Products
Michael Zdanowski (US) – HEMACORDTM: The First FDA Approved Allogeneic (Cord Blood Derived) Stem Cell Product A Case Study: From Research to IND to BLA
For GE: Jiwen Zhang (US) and Firman Ghouze (US)
For CellGenix: Felicia Rosenthal (DE)
For Lonza: Kim Warren (US)

Plenary Session 2 – Cardiovascular Cell Therapy

Chair: Michael Laflamme (US)
Rachel Smith (US) – Autologous and Allogeneic Cardiosphere-Derived Cells for Heart Regeneration
April Stempein-Otero (US) – Understanding Mechanisms of Cell Based Therapy in the Human Heart
Wolfram Zimmermann (DE) – Therapeutic Heart Muscle from Oocytes
Michael Laflamme (US) – Electromechanical Integration and Arrhythmogenic Risk of Human Embryonic Stem Cell-Derived Cardiomyocyte Transplantation

Technical Applications Track 2 – Roudntable Debate: Pros and Cons in the Cellular Therapy Field

Topic #1: Should closed systems and/or classified facilities be required for processing all cell therapy products?
Topic #2: Should donors of HPC or other cell therapy products be financially compensated?
Chair: Lizette Caballero (US)
Paul Eldridge (US), Ann Wilson (US), Martin Hildebrandt (DE), Karen Snow (US), Lynn O'Donnell (US), Michael Boo (US), Lizette Caballero (US), Renee Smilee (US)

Workshop 1 - ISCT/USP Joint Session: Ancillary materials

Co-Chairs: Elizabeth J. Read (US) and Fouad Atouf (US)
Elizabeth J. Read (US) – Ancillary Materials: Definitions, Regulatory Framework, and USP's Risk-Tiered Approach
Nicole Provost(US) – Ancillary Materials in Cell Therapy Product Development
Felicia Rosenthal (DE) – Cytokines and Growth Factor for Ex vivo Cell Culture

Workshop 2- Induced Cells for Neurological Disorders

Chair: Josef Priller (DE)
Josef Priller (DE) – Induced stem cells in research and therapy of neuropsychiatric disorders
Philip Horner (US) – Neural stem cells derived from human iPS improve forelimb recovery following spinal cord injury
Philip Schwartz (US) – An approach to immune-matched neurotherapy in pediatric neurodegenerative diseases

Workshop 3- Expansion of Cord Blood

Chair: Colleen Delaney (US)
Elizabeth Csaszar (CA) – Harnessing hematopoietic stem cell self-renewal to enable therapies
Elizabeth J. Shpall (US) – Graft Engineering: The future of cord blood transplantation
Colleen Delaney (US) – Enhancing myeloid recovery after cord blood transplantation by infusion of cord blood stem/progenitor cells expanded in the presence of Notch ligand

Strategies for Commercialization Track 3- Scalable Technologies for Phase 3 and Cell Therapy Commercial Products

Co-Chairs: Frida Grynspan (IL) and Steve Oh (SG)
Jaeseung Lim (KR) – The autologous T cell therapy products in Korea
Jef Pinxteren (BE) – Extensive quality control of MultiStem cells isolated and expanded using the on the Quantum CES
Steve Oh (SG) – Stem cell bioprocessing: Superior cell expansion and differentiation on microcarriers
Lye Theng Lock (US) – Scalable kSep Process for Therapeutic Cell Concentration and Residual Clearance

Technical Applications Track 3 - Optimizing Clinical Outcomes of Cord Blood Transplantation through Enhanced Selection, Testing and Preparation

Chair: Donna Regan (US)
Joanne Kurtzberg (US) – How does cord blood potency impact clinical outcomes after cord blood transplantation?
Donna Wall (CA) – Preparation of cord blood for infusion: wash, no wash, or somewhere in between
Karen Ballen (US) – Optimal Cord Blood Unit Selection: Beyond Cell Dose

Thursday, June 7th

Technical Session 3- Cell Engineering

Chair: David DiGiusto
David DiGiusto (US) – Zinc Finger Nuclease mediated genomic editing of CCR5 in human hematopoietic stem and progenitor cells for clinical application in HIV gene therapy
Christine Brown (US) – Phenotypic and Functional Attributes of Lentivirus Modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale

Technical Session 4 - Funding for Early Stage Cell Based Therapies

Chair: Ellen Feigal (US)
Ellen Feigal (US) – Advancing Stem Cell Science Towards Therapies for Patients: CIRM's Initiatives and Funding Opportunities
Lis Welniak (US) – NHLBI Update on Funding and Resources for Studies in Cellular Therapies

Strategies for Commercialization Track 4 - Cell Characterization Assays

Co-Chairs: Wouter Van't Hof (US) and Timothy Fong (US)

Wouter Van't Hof (US) – Potency assay development for MultiStem, a stromal cell therapy product
Verna McErlane (UK) – Cell Therapy Product Characterisation........a miRNA-based perspective
David Wilson (US)-

Technical Applications Track 4 - Preparing Agreements for Contract Services

Chair: Ann Wilson (US)
Victor Lemas
(US) – Why you need to care about Internal Agreements?
Liz Cardwell (US) – Great Expectations: External Supplier Agreements

Plenary Session 3 – Stem cells for Gene Therapy

Chair: Hans-Peter Kiem (US)
Christoph Klein (DE) – Hematopoietic stem cell gene therapy for Wiskott-Aldrich Syndrome- efficacy and risks
Nathalie Cartier (FR) – Hematopoietic stem cell gene therapy for X-linked Adrenoleukodystrophy
Andrew Scharenberg (US) – Cell engineering with rare cleaving nucleases: technology landscape and applications

Technical Applications Track 5- Translating Science from Bench to Bedside with Real Case Scenarios

Chair: Renee Smilee (US)
A Novel Strategy to Enhance Mesenchymal Stem Cell Migration and Therapeutic Efficacy (Abstract # 16)
Ian Nicoud (US) – Part 1: From model to manufacture- creating a clinical product from research findings
Jason Carstens (US) – Part 2: Process Development and Design for Manufacturing
Tory Lake (US) – Part 3: Navigating the regulatory path to clinical application
Colleen Delaney (US) – Part 4: Realizing the goal- clinical outcomes and future directions

Oral Abstract Presentations 4 – Basic Biology of Non-Hematopoietic Stem Cells/Non-Hematopoietic Stem Cells Towards Clinics

Chair: Luc Sensebé (FR)
Human Mesenchymal Stem Cells Express Proteins Belonging to or Related to the IL1 Family that Contribute to their Anti-Inflammatory Activity (Abstract # 17)
Speaker: Siddaraju Boregowda (US)
Regulating Human Mesenchymal Stem Cells for Osteogenic Tissue Repair by P63 and P38 Isoforms (Abstract # 18)
Speaker:Guy Howard (US)
MSC Functionality and Robustness of the MSC Expansion Process are Critically Dependent on Tissue Source and Expansion Conditions (Abstract #19)
Speaker: Helene Roelofs (NL)
Mesenchymal Stromal Cell Therapy for Refractory Crohn's Disease (Abstract # 20)
Speaker: Janice Fogarty (AU)
Mobilization of Mesenchymal Stem Cells from the Bone Marrow to Peripheral Blood (Abstract # 21)
Speaker: Ian McNiece (US)
Prospectively Isolated Scavenging Bone-Marrow Sinusoidal Endothelial Cells Home to, and Revascularize the Bone Marrow of Transplanted Ablated Recipients (Abstract # 16)
Speaker: Susie Nilsson (AU)

Oral Abstract Presentations 5 - Hematopoietic Stem Cells

Co-Chairs: Susie Nilsson (AU) and Shelly Heimfeld (US)
Optimizing Megakaryocyte Polyploidization Increases Platelet Release in Culture (Abstract # 22)
Speaker: Mauro Avanzi (US)
Hematopoietic Stem Cells and Megakaryocyte Progenitors and Their Subsets Differ in Normal and Meyeloproliferative Disease States (Abstract # 23)
Speaker: Varda Deutsch (IL)
ALDHBR Content of Segments from Banked Cord Bloods Predicts Engraftment After Cord Blood Transplantation (Abstract #24)
Speaker: Kevin Shoulars (US)
Nanoliter Droplet Vitrification for Blood and Stem Cell Cryopreservation (Abstract # 25)
Speaker: Claudia Zylberberg (US)
Luminometric Determination of Progenitor Cell Function in Cryopreserved Peripheral Blood Stem Cell Harvests (Abstract # 26)
Speaker: Beate Wagner (DE)
What Clinical Characteristics of African American Mothers and Babies Favorable Influence Cord Blood Potency? Defining Parameters That Can Guide Public Cord Blood Collection (Abstract # 27)
Speaker:Kristin Page (US)

Strategies for Commercialization Track 5- Key Considerations for Cell Therapy Pivotal Trials and Beyond

Chair: Darin Weber (US)

Lynn Allen-Hoffman (US) – Great Expectations: Readying you Technology for Regulatory Assessment
Paul Williamson (US) – Development of Cell-based Therapies in a Large Organization: Orchestrate for Success
Darin Weber (US) – Insights and Considerations in Preparing for Phase 3 Cell Therapy Studies

Technical Applications Track 6- Regulations Around the World

Chair: Christopher Bravery (UK)

Martin Bleasdale (AU) – Regulations around the world- an Australian perspective
Mark Lowdell (UK) – Regulation of ATMP trials in the EU: is it breaking the 'virtuuos cycle'?
Halvard Bönig (DE) – Academia and advanced cell therapy: A German Perspective
Jaeseung Lim (KR) – The regulation and the development of cell therapy products in Korea

Plenary Session 4 – Regenerative Medicine and Positioning for Commercial Success

Co-Chairs: Kurt Gunter (US) and Tracey Lodie (US)
John McMannis (US) – "Off the Shelf" Stem Cell Products for Regenerative Medicine
Mark Frohlich (US) – Commercialization of Sipuleucel-T, the first FDA Approved Autologous Cellular Immunotherapy for Cancer
Gil Beyen (BE) – Lessons from the commercial roll out of ChondroCelect in Europe

Technical Applications Track 7 - New Perspectives in Cell Selection

Chair: Martin Hildebrandt (DE)
Stanley Riddell (US) – Selecting defined subsets of T cells for genetic modification and cell therapy
Carolyn Keever-Taylor (US) – Cell enrichment and depletion using the CliniMACS device: Factors affecting outcome
Dirk Busch (DE) – Reversible cell labeling technologies for clinical cell processing and purification

Workshop 4 - ISCT Reimbursement Roundtable Highlights

Chair: Richard Maziarz (US)
Robert Deans (US)
Richard Maziarz (US)

Workshop 5 - Platelet and Erythrocyte Production Progress in Manufacturing and Drug Delivery

Chair: Luc Douay (FR)
Luc Douay (FR) – In vitro red blood cell production: state of the art
Jo Anna Reems (US) – In vitro platelet production: myth or future reality
Yan Godfrin (FR) – Red Blood Cells for a New Drug Formulation

Strategies for Commercialization Track 6 - Sourcing Biological Materials and Managing Supply Chains- Quality Considerations

Chair: Scott Burger (US)
Dominic Clarke (US) – Managing Particulates in Cellular Therapy
Gaytha McPherson (US) – Optimizing Apheresis Cellular Collections
Emmanuelle Charton (Council of Europe) – How the European Pharmacopoeia can contribute to the quality of raw materials for the production of cellular and gene transfer products
Hermann Bohnenkamp (DE) – Controlled, standardized cytokines and cell culture media for manufacturing Advanced Therapies

Technical Applications Track 8 - Challenges New Customers Present to the CT Lab

Chair: Lynn O'Donnell (US)
Carolyn Lutzko (US) – The Art and Science of Translating a Cell Therapy from Mouse to Man
Tom Leemhuis (US) – Teaching surgeons how to do cell therapy
Deborah Griffin (US) – Practical methods for regulatory compliance and documentation of new protocol implementation for the CT Lab

Friday, June 8th

Technical Session 5 - Ex-vivo and In-vivo Graft Engineering

Chair: Stephan Mielke (DE)
Stephan Mielke (DE) – TH9402-based, ex vivo allodepletion to improve matched and mismatched transplants
Catherine Bollard (US) – Ex vivo expanded multi-virus specific T cells to reduce infectious comlications after allogeneic stem cell transplantation
Paul O'Donnell (US) – Cyclophosphamide-Induced Tolerance in BMT

Technical Session 6 - TPP Workshop

Chair: Ellen Feigal (US)
Ellen Feigal (US) – Target Product Profile – Key Guide in Product Development
Wilson Bryan (US) – Target Product Profile – A Regulatory Perspective

Technical Session 7 - Freezing of Living Cells for Cellular Therapy: A Challenge for Biomedical Scientists

Chair and Speaker: Dayong Gao (US)

Strategies for Commercialization Track 7 - Strategic Partnering and Technology Transfer

Chair: Dean Tozer (US)
Dean Tozer (US) – Creating value in today's Regenerative Medicine environment
Kenneth L. Harris (US) – Increase the Success of CT Clinical Trials: An Affordable High Quality Model
Timothy Davidson (US) – Global Strategy for Successful Cell Therapy Products

Technical Applications Track 9 - Point of Care Devices in Cell Therapy

Chair: Dominic Wall (AU)
Dominic Wall (AU) – New Technologies in Cell Therapy Manufacturing
David James (AU) – Developing and implementing new technology for cell therapy

Plenary Session 5 – Regeneration Revisited

Chair: John Rasko (AU)
Andras Nagy (CA) – Toward understanding the process of somatic cell reprogramming to pluripotency
Shahin Rafii (US) – Vascular niche-derived angiocrine factors initiate and sustain organ regeneration

Technical Applications Track 10 – Lean Process for Processing Laboratories: When can we use it with examples

Chair: Karen Foster (US)
Brent McKinnon (US) – ViaCord Cord Blood Processing - Matching Unit Cycle Time to Take Time
Jennifer Glejf (US) – Getting LEAN in the Human Cell Therapy Lab: How Applying LEAN Principals to One Area of the Lab Caught Like Wildfire

Oral Abstract Presentations 6 – Lab Practices/Legal and Regulatory Affairs

Co-Chairs: Deborah Lamontagne (US) and Shirley Bartido (US)

Post Thaw CD34 Recovery and Viability of Hematopoietic Progenitor Cells is a Valuable Clinical Tool in Autologous Blood and Marrow Transplants (Abstract # 29)
Speaker: Susan Berrigan (CA)
Stability of Thawed Hematopoietic Progenitor Cells (HPC) in Dimethyl Sulfoxide (DMSO) in Filtered and Unfiltered Producs (Abstract # 28)
Speaker: Mehraboon Irani (US)
Establishing the Necessary Data to Model the Future Resource Requirements and Predicted Healthcare Targets for Cell Therapy as Part of Routine Clinical Practice (Abstract # 30)
Speaker: Emily Culme-Seymour (UK)
Regulatory Implications of Allogeneic Cell Banking Strategy (Abstract #31)
Speaker: Christopher Bravery (UK)

Oral Abstract Presentations 7- Regenerative Medicine

Chair: Shelly Heimfeld (US)

Systemic Human Orbital Fat-Derived Stem Cell Transplantation Ameliorates Acute Inflammation in Lipopolysaccharide-Induced Acute Lung Injury (Abstract # 32)
Speaker: Jennifer Ho (TW)
A Neo-Kidney Augment Product for Kidney Regeneration in a Large Animal Model of Chronic Kidney Disease (Abstract # 33)
Speaker: Deepak Jain (US)
Contribution of Human Induced Pluripotent Stem Cell Derived Endothelial Cells in Vascular Regeneration of Bleomycin-Induced Scleroderma Mouse Model (Abstract # 34)
Speaker:Nasser Aghdami (IR)
Standardized Quality Control and Cell Equivalency for Xeno-Free Multistem, an Adherent Stem Cell Therapeutic (Abstract #35)
Speaker: Annelies Bogaerts (BE)

Technical Applications Track 11- Selling Cellular Therapies to Consumers: The good, the bad and the ugly

Chair: Bruce Levine (US)
Aaron Levine (US) – Assessing patients' experiences with unproven stem cell interventions
Timothy Caulfield (CA) – The Big Sell: The Marketing of Unproven Therapies

Workshop 6 - ISCT/PACT Joint Session: PACT II: Scope of Projects at Pre-Clinical and Manufacturing Stages of Development

Co-Chairs: Shelly Heimfeld (US) and Les Silberstein (US)
Les Silberstein
(US) – Objectives of the PACT program
Myriam Armant (US) – Examples of PACT II Enabled Translational and Clinical Applications at CHCT
David McKenna (US) – Challenges in Moving Cell Therapies to the Clinical Arena: The Minnesota PACT Experience
Adrian Gee (US) – PACT-Supported Development of Virus-Detected T Cell Therapy
Larry Couture (US) – Process development for scalable cardiomyocyte differentiation from hES cells

Workshop 7 - MSC Production and Clinical Uses: Impact of Production Methods on Potency and Safety

Co-Chairs: Luc Sensebé (FR) and Mauro Krampera (IT)
Hillard Lazarus (US) – Novel uses for MSCs and MAPCs
David Stroncek (US) – BM MSCs Production and Assessment for Clinical Applications
Luc Sensebé (FR) – MSCs from Safety Concerns to Controls

Strategies for Commercialization Track 8 - Tissue Engineering in 2012: Lost in Commercial Translation?

Chair: Sharon Presnell (US)
Sharon Presnell (US) – Capturing the value from science: Translating promising research into a tangible asset
Dean Tozer (US) – Ushering an innovative regenerative medicine product from development to the market
Timothy Fong (US) – From Idea to Product: The pathway from academic innovation to a commercial manufacturing process

Technical Applications Track 12 - Strenuous Standards: Savvy Solutions

Chair: Lynn O'Donnell (US)
Douglas Padley (US) – The Search for Balance: Control vs. Creativity in the Development and Implementation of Novel Cellular Therapy Product Trials
Jessica Carmen (US) – Molecular Trilineage Assay for Identity Testing of hMSCs
John Duguid(US) – Validation of Rapid Mycoplasma Testing using Real-Time PCR
Michele Cottler-Fox (US) – Garbage in, garbage out: a predictive formula to improve efficiency and quality for HPC collection and processing facilities

Plenary Session 6 – Immunotherapy and T-Cells

Chair: Philip Greenberg (US)

Philip Greenberg (US) - T cells vs. tumors: Preparing T cells for the kill
Michael Jensen (US) – Enhancing the IQ of CAR-modified T Cells
Renier Brentjens (US) – Chimeric antigen receptor (CAR) modified T cells as a novel approach to immuno-therapy of B cell malignancies

Technical Applications Track 13 - ISBT Labeling Implementation- Presentation of Real Scenarios

Co-Chairs: Lizette Caballero (US) and Leigh Sims Poston (US)
Kathy Watkins (US) – ISBT Labeling: One Small Lab's Implementation Experience
Mary McLeod (US) – Developing an ISBT 128 plan for Cell Therapy Labs and Apheresis Collection Facilities

© 2017 International Society for Cellular Therapy. All rights reserved.
ISCT, International Society for Cellular Therapy, and the ISCT logo are registered service marks of The International Society for Cellular Therapy.
The BEACON and lighthouse logo is a service mark of The International Society for Cellular Therapy.